The product is under Phase 2a (POC) clinical trials in five EU countries for the treatment of Irritable Bowel Syndrome (IBS). OMS210 has an innovative Serotonin 5-HT3 receptor-binding profile as a partial agonist. In comparison to the existing full 5-HT3 receptor agonist or antagonist, OMS210 is expected to avoid excessive diarrhea or constipation and to have a moderate suppression of diarrhea with remaining normal bowel movement.

LOTUS PHARMACTUTICAL CO., LTD. has an exclusive world-wide development, manufacturing and sales rights of OMS210.